Significant Improvement With Ivarmacitinib After Suboptimal Response to Tofacitinib in Severe Alopecia Areata: A Case Report and Literature Review

February 2026 in “ Frontiers in Immunology ”

Zulin Wan, Ying Wang, Dingquan Yang

ivarmacitinib JAK1 inhibitor alopecia areata tofacitinib SALT score JAK inhibitors

From the encyclopedia

Alopecia Areata →

autoimmune disorder causing patchy hair loss

Tofacitinib →

a JAK inhibitor for alopecia areata and other autoimmune conditions

Studysummary This case report highlights significant improvement in a patient with severe alopecia areata who responded well to ivarmacitinib after a suboptimal response to another JAK inhibitor, tofacitinib, suggesting ivarmacitinib as a potential alternative for tofacitinib-refractory cases.

Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer

This case report discusses the effectiveness of ivarmacitinib, a highly selective JAK1 inhibitor, in treating severe alopecia areata (AA) in a 26-year-old female who had a suboptimal response to tofacitinib. After switching to ivarmacitinib, her SALT score improved significantly from 100 to 35, indicating substantial hair regrowth. The report suggests that ivarmacitinib's higher JAK1 selectivity may enhance its efficacy and tolerability compared to tofacitinib. It proposes that switching JAK inhibitors could be a viable strategy for managing severe AA, though further studies with larger sample sizes are necessary to validate these findings.

View this study on public-pages-files-2025.frontiersin.org →

Discuss this study in the Community →

Research cited in this study

14 / 14 results

research Ivarmacitinib for the Treatment of Adults with Severe Alopecia Areata: Results from a Phase 3 Trial

4 citations , September 2025 in “Journal of the American Academy of Dermatology”

research Considerations for the Treatment Strategy of Relapse After Tofacitinib Therapy in Alopecia Areata

July 2025 in “Journal of Cosmetic Dermatology”

In this study, authors present a case where a 26-year-old patient with alopecia areata experienced relapse after initially responding to Tofacitinib, mitigated by corticosteroids, highlighting challenges and potential insights into the treatment and pathogenesis of the condition.

research Alopecia Areata: Pathogenesis, Diagnosis, And Therapies

21 citations , April 2025 in “MedComm”

This review explores the complex factors involved in alopecia areata, such as immune and genetic influences, and discusses advances in diagnostic and therapeutic approaches, while reporting no new clinical results.

research Baricitinib for the Treatment of Moderate-To-Severe Alopecia Areata

January 2025 in “Balkan Medical Journal”

Baricitinib helps regrow hair in severe alopecia areata and is safe, but more research is needed.

Screening for Latent Infectious Disease in Patients with Alopecia Areata Before Initiating JAK Inhibitors Therapy: A Single-Center Real-World Retrospective Study

research Screening for Latent Infectious Disease in Patients with Alopecia Areata Before Initiating JAK Inhibitors Therapy: A Single-Center Real-World Retrospective Study

October 2023 in “Frontiers in medicine”

This study analyzed screening data from 218 alopecia areata patients before starting Janus kinase inhibitors, revealing the importance of pre-treatment screening due to risks of infections like tuberculosis and hepatitis B, with 74.8% of patients proceeding to treatment in real-world settings.

research Dupilumab Therapy for Alopecia Areata in a 4-Year-Old Patient Resistant to Baricitinib

October 2023 in “Frontiers in Medicine”

In a reported case, researchers observed full hair regrowth on the scalp, eyebrows, and eyelashes of a 4-year-old with alopecia universalis after 10 months of treatment with dupilumab, following resistance to baricitinib.

research Efficacy and Safety of Ritlecitinib in Adolescents with Alopecia Areata: Results from the ALLEGRO Phase 2b/3 Randomized, Double-Blind, Placebo-Controlled Trial

48 citations , July 2023 in “Pediatric Dermatology”

This study found that among adolescents with alopecia areata and significant hair loss, treatment with ritlecitinib resulted in greater hair regrowth and self-reported improvement compared to placebo over 48 weeks, with common side effects including headache, acne, and nasopharyngitis.

research Switching Between Tofacitinib and Baricitinib in Alopecia Areata: A Review of Clinical Response

April 2023 in “Journal of the American Academy of Dermatology”

This study aimed to evaluate the outcomes of switching between two JAK inhibitors, tofacitinib and baricitinib, in treating alopecia areata, due to the lack of data on their comparative efficacy.

research Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata Over 52 Weeks in Phase III Trials

20 citations , February 2023 in “American Journal of Clinical Dermatology”

In this study, 40.9% of patients taking 4 mg baricitinib and 21.2% taking 2 mg achieved significant hair regrowth over 52 weeks, indicating potential long-term benefits for adults with severe alopecia areata without introducing new safety concerns.

Ideal JAK Inhibitor for Alopecia Areata: Baricitinib, Tofacitinib, Ritlecitinib, or Ifidancitinib - Revisiting the Immunomechanisms of the JAK Pathway

research Ideal JAK Inhibitor for Alopecia Areata: Baricitinib, Tofacitinib, Ritlecitinib, or Ifidancitinib - Revisiting the Immunomechanisms of the JAK Pathway

January 2023 in “Indian Dermatology Online Journal”

This review discusses the role of the JAK/STAT pathway in managing alopecia areata and emphasizes the need for further research to determine the ideal JAK inhibitor, as it reports no new clinical results.